Analytical Method Development and Validation for Clofazimine in Human Plasma and Application of LC–MS/MS Based Methods for Clofazimine and Bedaquiline in Indian MDR‐TB Patients Stratified by HIV Coinfection
Journal of Mass Spectrometry · 2026
DOI: 10.1002/jms.70093 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Mass Spectrometry, 2026. Verfasst von Rohan V Lokhande und 16 weiteren Autor:innen. Beteiligte Einrichtung: Research Laboratories, P.D. Hinduja Hospital and Medical Research Centre, Mumbai, India. Hauptthemen laut MEDLINE: Clofazimine, Diarylquinolines, Tandem Mass Spectrometry, HIV Infections. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS, NIAID NIH HHS, P. D. Hinduja Hospital and Medical Research Centre.
Abstract (Originalsprache)
Multidrug‐resistant tuberculosis (MDR‐TB) remains a major cause of morbidity and mortality worldwide, with people living with HIV experiencing persistently poor treatment outcomes. Clofazimine and bedaquiline are cornerstone drugs in contemporary all‐oral MDR‐TB regimens, yet their complex pharmacokinetics and substantial interindividual variability complicate regimen optimisation, particularly in vulnerable populations. Robust plasma‐based drug quantification is essential to characterise exposure–response relationships and inform individualised therapy. We developed and validated a rapid, sensitive and specific liquid chromatography–tandem mass spectrometry assay for quantifying these drugs in human plasma. The methods were successfully applied on plasma samples from study participants with MDR‐TB with or without HIV coinfection who received clofazimine and bedaquiline as part of MDR‐TB therapy assessing the Cmax, Tmax and AUC in both groups. The method addresses key analytical challenges posed by clofazimine's extreme lipophilicity and reliably quantifies concentrations across a broad, clinically relevant range, including potentially toxic exposures. Linearity was obtained between 0.0313 to 4.0 mg/L, and the method met bioanalytical method validation criteria along with interlab comparison with a reference laboratory, all within acceptable limits. We observed significantly lower Cmax concentrations of both drugs among HIV‐infected participants compared to HIV‐uninfected participants ( p = 0.011 for clofazimine and p = 0.02 for bedaquiline), highlighting the need for therapeutic drug monitoring in this vulnerable group. This work provides a robust analytical foundation for pharmacokinetic, therapeutic drug monitoring and exposure–response studies of key MDR‐TB drugs and supports efforts to optimise treatment outcomes, especially among people living with HIV.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Research Laboratories, P.D. Hinduja Hospital and Medical Research Centre, Mumbai, India.
- Department of Chemistry, Satish Pradhan Dnyanasadhana College, Thane, India.
- Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.
- Center for Infectious Diseases in India, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
- Center for Tuberculosis Research, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
- Bloomberg School of Public Health, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
ORCID-Profile: Prerna R Arora, Ganesh R Bhagure, Camilla Rodrigues, Amita Gupta, Vidya Mave, Priyanka Raichur, Rifa Khan, Lubbe Wiesner, Jeffrey A Tornheim, C Robert Horsburgh, Tester F Ashavaid
Förderung
- NIH HHS
- NIAID NIH HHS
- P. D. Hinduja Hospital and Medical Research Centre
- Department of Science and Technology, Ministry of Science and Technology, India
- Department of Biotechnology, Ministry of Science and Technology, India
- NIH/DBT RePORT India Consortium
- RePORT International Coordinating Center
- National Institutes of Health
Zitieren
APA
Lokhande, R. V., Arora, P. R., Bhagure, G. R., Joubert, A., Udwadia, Z. F., Rodrigues, C., Gupta, A., Mave, V., Raichur, P., Gaikwad, S., Khan, R., Pradeep, A., Wiesner, L., Tornheim, J. A., Horsburgh, C. R., Ashavaid, T. F., & MDR‐TB MUKT and RePORT India Team, Indo‐South Africa Study Team and PREEMPT Study Teams (2026). Analytical Method Development and Validation for Clofazimine in Human Plasma and Application of LC–MS/MS Based Methods for Clofazimine and Bedaquiline in Indian MDR‐TB Patients Stratified by HIV Coinfection. Journal of Mass Spectrometry. https://doi.org/10.1002/jms.70093
Vancouver
Lokhande RV, Arora PR, Bhagure GR, Joubert A, Udwadia ZF, Rodrigues C, et al. Analytical Method Development and Validation for Clofazimine in Human Plasma and Application of LC–MS/MS Based Methods for Clofazimine and Bedaquiline in Indian MDR‐TB Patients Stratified by HIV Coinfection. Journal of Mass Spectrometry. 2026. doi:10.1002/jms.70093
BibTeX
@article{Lokhande2026,
author = {Lokhande, Rohan V and Arora, Prerna R and Bhagure, Ganesh R and Joubert, Anton and Udwadia, Zarir F and Rodrigues, Camilla and Gupta, Amita and Mave, Vidya and Raichur, Priyanka and Gaikwad, Sanjay and Khan, Rifa and Pradeep, Amrose and Wiesner, Lubbe and Tornheim, Jeffrey A and Horsburgh, C Robert and Ashavaid, Tester F and MDR‐TB MUKT and RePORT India Team, Indo‐South Africa Study Team and PREEMPT Study Teams, MDR‐TB MUKT and RePORT India Team, Indo‐South Africa Study Team and PREEMPT Study Teams},
title = {Analytical Method Development and Validation for Clofazimine in Human Plasma and Application of LC–MS/MS Based Methods for Clofazimine and Bedaquiline in Indian MDR‐TB Patients Stratified by HIV Coinfection},
journal = {Journal of Mass Spectrometry},
year = {2026},
doi = {10.1002/jms.70093}
}
EUVIMED